Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 17, Issue 1-2, 2004, Pages 100-108

  Wynn, Zakiya J ^a   Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Agitation; Alzheimer's disease; Apathy; Cholinesterase inhibitors; Depression; Neuropsychiatric inventory; Psychosis

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; PERPHENAZINE; RIVASTIGMINE; TACRINE; XANOMELINE;

AGITATION; ALZHEIMER DISEASE; APATHY; BEHAVIOR; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DEPRESSION; EMOTIONAL DISORDER; HALLUCINATION; HUMAN; MENTAL DISEASE; NEUROPSYCHIATRY; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEPRESSION; HUMANS; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS;

EID: 0345059945     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074281     Document Type: Review

References (70)

1. Jorm AF: Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci 1991; 240:218-222.
2. Prince M: The need for research on dementia in developing countries. Trop Med Int Health 2002;2:993-1000.
3. Lyketsos CG, Breitner JC, Robins PV: An evidence-based proposal for the classification of neuropsychiatric disturbances in Alzheimer's disease. Int J Geriatr Psychiatry 2001;16: 1037-1042.
4. Cummings JL: Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15.
5. Hogan DB, Patterson C: Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias - Review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 2002;29:306-314.
6. Mirra SS, Heyman A, McKeel D, et al: The consortium to establish a registry for Alzheimer's disease (CERAD). 2. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-486.
7. Bartus RT, Dean RL 3rd, Beer B, et al: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-417.
8. Cummings JL, Beck C: The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6: S64-S78.
9. Procter AW, Lowe SL, Palmer AM, et al: Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 1988;84:125-140.
10. Dunnett SB, Whishaw IQ, Jones GH, Bunch ST: Behavioral, biochemical, and histochemical, effects of different neurotoxic amino acids injected into the nucleus basalis magnocellularis of rats. Neuroscience 1987;20:653-669.
11. Anagnostaras SG, Murphy GG, Silva AJ, Rahnama NP, Mitchell SL: Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-58.
12. Sunderland T, Tariot PN, Cohen RM, et al: Anticholinergic sensitivity in patients with dementia of the Alzheimer's type and age matched controls. Arch Gen Psychiatry 1987; 44:418-426.
13. Sunderland T, Tariot P, Newhouse PA, et al: Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res 1988; 13:371-389.
14. Gorman DG, Read S, Cummings JL: Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-234.
15. Thal LJ, Ferguson JM, Mintzer J, Raskin A, et al: A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 1999;52:1146-1152.
16. McKeith I, Del Ser T, Spano P, et al: Efficacy of rivastigmime in dementia with Lewy bodies: A randomized, double-blinded, placebo-controlled international study. Lancet 200;356: 2031-2036.
17. Minger SL, Esiri MM, McDonald B, et al: Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000;55:1460-1467.
18. Caulfield MP, Birdsall NJ: Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-290.
19. 2 binding in the cortex. Neurology 2001;805-811.
20. Bodick NC, Offen WW, Levey AL, Cutler NR, et al: Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;4:265-473.
21. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R: Natural history of behavioral changes and psychiatric symptoms in Alzheimer's disease: A longitudinal study. Br J Psychiatry 1999;174:39-44.
22. Levy ML, Cummings JL, Fairbanks LA, et al: Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatrry 1996;153:1438-1443.
23. Mega M, Cummings JL, Fiorello T, Gornbein J: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.
24. Landes AM, Sperry SD, Strauss ME, et al: Apathy in Alzheimer's disease. J Am Geriatr Soc 2001;49:1700-1707.
25. Levy ML, Cummings JL, Fairbanks LA, et al: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314-419.
26. Craig AH, Cummings JL, Fairbanks L, et al: Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-1120.
27. McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C: Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc 2002;8:373-381.
28. Tractenberg RE, Weiner MF, Thal LJ: Estimating the prevalence of agitation of community-dwelling persons with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2002;14:11-18.
29. Hirano N, Mega MS, Dinov ID, et al: Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. Arch Neurol 1988;23:616-620.
30. Tekin S, Mega MS, Masterman DL, et al: Orbitofrontal and anterior cingulate cortex: Neurofibrillary tangle burden is associated with agitation in Alzheimer's disease. Ann Neurol 2001; 49:355-361.
31. Chen P, Ganguli M, Mulsant BH, et al: The temporal relationship between depressive symptoms and dementia. Arch Gen Psychiatry 1999;56:261-266.
32. Lyketsos CG, Steele C, Baker L, et al: Major and minor depression in Alzheimer's disease: Prevalence and impact. J Neuropsychiatry Clin Neurosci 1997;9:556-561.
33. Olin JT, Schneider LS, Katz IR, et al: Provisional diagnostic criteria for depression of Alzheimer disease: Rationale and background. Am J Geriatr Psychiatry 2002;10:129-141.
34. Lyketsos CG, Steele C, Galik E, et al: Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry 1999; 156:66-71.
35. Hirano N, Mori E, Ishii K, et al: Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 1998;50:380-383.
36. Jeste DV, Finkel SI: Psychosis of Alzheimer's disease and related dementias. Am J Geriatr Psychiatry 2000;8:29-34.
37. Cooper JK, Mingas D, Verma M, et al: Psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 1991;6:721-726.
38. Ballard C, Saad K, Patel A, et al: The prevalence and phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiatry 1995;10:477-485.
39. Gormley N, Rizwan MR: Prevalence and clinical correlates of psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 1998; 13:410-414.
40. Wilson RS, Gilley DW, Bennett DA, et al: Hallucinations, delusions, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;69:172-177.
41. Rymer S, Salloway S, Norton L, et al: Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord 2002;16:248-253.
42. Spruytte N, Van Audenhove P, Lammertyn F: Predictors of institutionalization of cognitively impaired elderly cared for by their relatives. Int J Geriatr Psychiatry 2001;16:1119-1128.
43. Stern Y, Tang MX, Albert MS, et al: Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 227:806-812.
44. Dyer C, Pavlik VN, Murphy K, et al: The high prevalence of depression and dementia in elder abuse or neglect. J Am Geriatr Soc 2000;48: 205-208.
45. Beeri MS, Werner P, Davidson M, Noy S: The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling in Alzheimer's disease patients. Int J Geriatr Psychiatry 2002;17:403-408.
46. Murman DL, Chen Q, Powell SB: The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002;59:1721-1729.
47. Trinh N-H, Hoblyn J, Mohanty S, Yaffe C: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. JAMA 2003;289:210-216.
48. Winblad B, Engedal K, Engedal K, et al: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurol 2001;57:489-495.
49. Tariot PN, Cummings J, Katz I, et al: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49: 1590-1599.
50. Feldman H, Gauthier S, Hecker J, Velles B, for the Donepezil MSAD Study Investigators Group: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alz-heimer's disease. Neurology 2001;57:613-620.
51. Gauthier S, Feldman H, Hecker J, for the MSAD Study Investigators Group: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404.
52. Mega MS, Materman DM, O'Connor S, et al: The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.
53. Mega MS, Dinov ID, Lee L: Orbital and dorsolateral frontal perfusion deficit associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2000;12:209-218.
54. Cummings JL, Donohue JA, Brooks RL: The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:134-140.
55. Matthews HP, Korbey J, Wilkinson DG, Rowden J: Donepezil in Alzheimer's disease: Eighteen-month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000; 15:713-720.
56. Bergman J, Brettholz I, Shneidman M, Lerner V: Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type. Clin Neuropharmacol 2003;26: 88-92.
57. Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998;11:211-216.
58. Tariot PN, Solomon PR, Morris JC, et al, for the Galantamine USA-10 Study Group: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
59. Wilkinson DG, Hock C, Van Baelen B, Schwalen S: Galantamine provides broad benefits in patients with' Alzheimer's disease (MMSE≤12) for up to six months. Int J Clin Pract 2002;56:509-514.
60. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D: Effects of flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-595.
61. Davis K, Thal L, Gazmu E, et al: A double-blind placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
62. Knapp MJ, Knopman DS, Solomon PR, et al: A controlled trial of tacrine in Alzheimer's disease. JAMA 1994;271:985-991.
63. Raskind MA, Sadowsky CH, Sigmund W, et al: Effect of tacrine on language, praxis and non-cognitive behavioral problems in Alzheimer's disease. Arch Neurol 1997;54:836-840.
64. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
65. Kaufer DI, Cummings JL, Christine D: Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998;10:55-63.
66. Becker R, Colliver J, et al: Effects of metrifonate, a long-acting cholinesterase inhibitor, for Alzheimer's disease: Report of an open trial. Drug Dev Res 1990;19:425-434.
67. Becker RE, Colliver JA, Markwell SJ, et al: Double-blind, placebo-controlled study of me-trifonate, an acetylcholinesterase inhibitor for Alzheimer's disease. Alzheimer Dis Assoc Disord 1996;10:124-131.
68. Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI, for the Metrifonate Study Group: The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. J Clin Psychiatry 1999;60: 313-325.
69. Morris JC, Cyrus PA, Orazem J, et al: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
70. Cummings JL, Nadel A, Masterman DM: Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. J Geriatr Psychiatry Neurol 2001;14:101-108.